MAB DISCOVERY GMBH has a total of 52 patent applications. It increased the IP activity by 31.0%. Its first patent ever was published in 2012. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are ALECTOR LLC, DECIMMUNE THERAPEUTICS INC and APTEVO RES & DEVELOPMENT LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 13 | |
#2 | WIPO (World Intellectual Property Organization) | 8 | |
#3 | Canada | 6 | |
#4 | China | 6 | |
#5 | United States | 6 | |
#6 | Australia | 3 | |
#7 | Brazil | 2 | |
#8 | Israel | 2 | |
#9 | Republic of Korea | 2 | |
#10 | Singapore | 2 | |
#11 | Mexico | 1 | |
#12 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Fischer Stephan | 46 |
#2 | Brandt Michael | 19 |
#3 | Beckmann Karsten | 18 |
#4 | Renninger Stephanie | 6 |
#5 | Michael Brandt | 3 |
#6 | Stephan Fischer | 3 |
#7 | Kazandjian Linda Veronique | 1 |
#8 | Karsten Beckmann | 1 |
#9 | Stephan Ficher | 1 |
#10 | Kazandjian Veronique Linda | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020221791A1 | Combination of her2 antibodies | |
AU2018335828A1 | Agonistic CD40 antibodies | |
EP3592384A1 | Antibodies specifically binding to human il-1r7 | |
EP3401332A1 | Anti-il-1r3 antibodies for use in inflammatory conditions | |
EP3313887A2 | Monoclonal anti-il-1racp antibodies | |
EP3241845A1 | Humanized anti-il-1r3 antibodies | |
EP3241847A1 | Her-2 binding antibodies | |
WO2014067642A1 | Method for the production of multispecific antibodies | |
EP2727941A1 | Method for the production of multispecific antibodies | |
EP2727942A1 | Bispecific antibodies against human EGFR, HER2, and HER3 | |
EP2727943A1 | Trispecific antibodies against human EGFR, HER2 and HER3 |